Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 102Breast Neoplasms 10Neoplasm Metastasis 8Prostatic Neoplasms, Castration-Resistant 6Triple Negative Breast Neoplasms 5Castration-resistant Prostate Cancer 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Metastatic Castration-resistant Prostate Cancer 3Prostate Cancer Metastatic 2Prostate Adenocarcinoma 2Ovarian Neoplasms 2Neoplasms 2Metastatic Castration-Resistant Prostate Cancer (mCRPC) 2Metastatic Castration-Resistant Prostate Cancer 2Metastatic Castration Resistant Prostate Cancer 2Castration Resistant Metastatic Prostate Cancer 2Carcinoma, Hepatocellular 2Adenocarcinoma of the Prostate 2Adenocarcinoma 2Uterine Cervical Neoplasms 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Ureteral Diseases 1Thrombocytosis 1Stomach Neoplasms 1Solid Tumor 1Salivary Cancer 1Recurrent Endometrial Endometrioid Adenocarcinoma 1

Interventions

enzalutamide 1delta 24-sterol reductase 1apalutamide 1Tape Recording 1Risk Assessment 1Preoperative Exercise 1Pilot Projects 1Nutritional Support 1Focus Groups 1Exercise 1Ethanol 1Bandages, Hydrocolloid 1Adiposity 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Patient Preference × enzalutamide × Clear all
NCT04409288 2024-01-05

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

Chinese University of Hong Kong

Phase 3 Terminated
74 enrolled
Genitourinary

Prostatic Neoplasms, Patient Preference

Data powered by HemOnc (CC BY 4.0) Colophon âš¡